Former F-star CEO joins NeoPhore board
Cambridge-based cancer immuno-oncology company NeoPhore has appointed former F-star CEO John Haurum as a non-executive director. Under his leadership, F-star successfully raised €200 million in equity and non-dilutive funding.
It also entered into a number of strategic collaborations with leading pharmaceutical and biotechnology companies in immune-oncology, including AbbVie and Merck KGaA, and in central nervous system disorders with Denali Therapeutics.
Dr Haurum was also instrumental in the development of the next wave of immunotherapies, establishing a substantial pipeline of candidates with the potential to benefit cancer patients.
NeoPhore chairman Robert James said: “John has an excellent track record of building and growing companies in the biotech industry and his expertise and scientific understanding of the IO space will be invaluable as we maximise the potential of our platform.”
Dr Haurum added: “NeoPhore is developing a breakthrough approach to increase detection and cancer rejection by the patient’s immune system and thereby is poised to create next-generation cancer therapies.
“ I am very excited to be joining NeoPhore and look forward to supporting the executive team and the board in developing its novel small molecule therapies to treat cancer and improve outcomes for patients.”
Dr Haurum has a long and successful career in the international biotech industry. Before F-star, he was VP Research at ImClone Systems; prior to this he was the CSO and co-founder of Symphogen. He is currently executive chairman of the board at Synklino.